EYEN Earnings Prediction
The chart below shows how EYEN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EYEN sees a +12.54% change in stock price 10 days leading up to the earnings, and a -10.05% change 10 days following the report. On the earnings day itself, the stock moves by +2.23%. This data can give you a slight idea of what to expect for the next quarter's release.
EYEN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.62K
35.64%
-92.82%
Gross Margin
-8055.20%
--
289.64%
Operating Margin
-451195.51%
-17.10%
773.37%
Net Margin
-485406.34%
-20.76%
893.54%
EPS
-0.11
-38.89%
-47.62%
No Data Available
EYEN Earnings Analysis
Eyenovia, Inc. Common Stock Corporation (EYEN.O) Earnings Conference Call
Positive
Transformation in Ophthalmic Medications: During the third quarter, we made significant progress towards transforming Eyenvia into a leader in improving outcomes from topical ophthalmic medications built around our Optijet technology.
Phase III Efficacy Data Readout: We are rapidly approaching a potential Phase III efficacy data readout for MicroPine, our pediatric progressive myopia product, which, if approved, provides entry to a multibillion-dollar addressable market opportunity.
Next-Generation Technology Advancement: We are advancing our next-generation Optijet technology and are excited about the progress and what this will mean for our profitability profile.
Product Commercialization Success: We have been commercializing our mydriasis product, MydCombi, the first FDA-approved product based on Optijet technology, and we also launched our second FDA-approved product, Clobetasol, an advanced ophthalmic steroid with a highly desirable profile.
Board Member Continuity: We are pleased that we will continue to have both Charlie and Sean as vital resources on our Board at this important time for Eyenvia.
Negative
Quarterly Net Loss Comparison: For the third quarter of 2024, we reported a net loss of approximately $7.9 million or $0.11 per share compared to a net loss of $7.3 million or $0.18 per share in the prior year quarter.
Quarterly Gross Loss Comparison: Gross loss for the third quarter was $131,000, which compares to $12,000 for the prior year quarter.
R&D Expense Comparison: Research and development expenses totaled approximately $3.5 million for the third quarter of 2024, compared to $3.6 million for the third quarter of 2023, reflecting a slight decrease.
Administrative Expense Increase: General and administrative expenses were approximately $3.7 million as compared to $2.9 million for the third quarter of 2023, representing an increase of 27.3%.
Operating Expenses Increase: Total operating expenses for the third quarter of 2024 were approximately $7.2 million as compared to $6.5 million for the same period in 2023, representing an increase of approximately 10.6%.
EYEN FAQs
How does EYEN typically perform around its earnings report dates?
Is Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EYEN Earning Call Sentiment
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EYEN.O
1.87%Positive
The earnings call reveals several concerns: a net loss increase, financial challenges, and resistance to new technology adoption. The Q&A section highlights management's vague responses, particularly concerning the CHAPERONE trial's power calculation and data review timeline, which may further unsettle investors. Despite the positive licensing agreement with Arctic Vision, the net proceeds from securities offerings and the potential for sales royalties, the financial health and market acceptance issues overshadow these positives. Overall, the sentiment leans negative, suggesting a potential stock price decline of -2% to -8%.